Table of Contents Table of Contents 3 List of Tables 5 List of Figures 5 Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6 Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7 Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8 Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9 Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10 Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11 Venture Financing 11 Alder Biopharma Raises US$38 Million In Series D Financing 11 Licensing Agreements 13 Teva Pharma Enters into Licensing Agreement with Alder Biopharma 13 Vitaeris Enters into Licensing Agreement with Alder BioPharma for Clazakizumab 14 Equity Offering 15 Alder Biopharma Raises USD100 Million in Private Placement of Preferred Stock 15 Alder BioPharma Raises USD172.5 Million in Public Offering of Shares 16 Alder BioPharma Raises USD143.8 Million in Public Offering of Shares 18 Alder BioPharma Raises USD230 Million in Public Offering of Shares 20 Alder BioPharma Raises USD203.6 Million in Public Offering of Shares 22 Alder Biopharma Raises USD88.8 Million in IPO 24 Debt Offering 26 Alder Biopharma Completes Underwriters Exercise of Over-Allotment Option of Public Offering of 2.5% Notes Due 2025 for USD287.5 Million 26 Alder Biopharmaceuticals Inc - Key Competitors 28 Alder Biopharmaceuticals Inc - Key Employees 29 Alder Biopharmaceuticals Inc - Locations And Subsidiaries 30 Head Office 30 Other Locations & Subsidiaries 30 Recent Developments 31 Financial Announcements 31 Nov 05, 2018: Alder BioPharmaceuticals reports third quarter 2018 financial and operating results 31 Aug 07, 2018: Alder BioPharmaceuticals reports second quarter 2018 financial and operating results 32 May 08, 2018: Alder BioPharmaceuticals Reports First Quarter 2018 Financial and Operating Results 33 Feb 26, 2018: Alder BioPharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results 34 Nov 07, 2017: Alder BioPharmaceuticals Announces Third Quarter 2017 Financial and Operating Results 36 Aug 08, 2017: Alder BioPharmaceuticals Announces Second Quarter 2017 Financial and Operating Results 37 Apr 27, 2017: Alder BioPharmaceuticals Announces First Quarter 2017 Financial and Operating Results 39 Feb 23, 2017: Alder BioPharmaceuticals Announces Fourth Quarter and Full Year 2016 Financial and Operating Results 41 Corporate Communications 43 Apr 26, 2018: Alder BioPharmaceuticals Appoints Jeremy Green to its Board of Directors 43 Apr 16, 2018: Alder BioPharmaceuticals Appoints Erin Lavelle to Newly Created Role of Chief Operating Officer 44 Mar 20, 2018: Alder BioPharmaceuticals Appoints Paul B. Cleveland as Interim President and Chief Executive Officer 45 Apr 04, 2017: Alder BioPharmaceuticals Appoints Wendy L. Yarno to its Board of Directors 46 Product News 47 03/06/2017: Alder BioPharmaceuticals Announces Presentations at 69th Annual American Academy of Neurology Meeting Supporting Development of Eptinezumab for Migraine Prevention 47 Clinical Trials 48 Jun 07, 2017: Alder to Present Migraine Prevention Data for Eptinezumab at 59th Annual Scientific Meeting of the American Headache Society 48 Apr 28, 2017: Alder BioPharmaceuticals Presents Positive Phase 2b Study Data for Eptinezumab at 69th Annual American Academy of Neurology Meeting 49 Apr 24, 2017: Alder BioPharmaceuticals Presents Additional Data from Eptinezumab Development Program at 69th Annual American Academy of Neurology Meeting 50 Appendix 51 Methodology 51 About GlobalData 51 Contact Us 51 Disclaimer 51

List of Tables Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2 Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6 Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7 Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8 Alder Biopharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9 Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10 Alder Biopharma Raises US$38 Million In Series D Financing 11 Teva Pharma Enters into Licensing Agreement with Alder Biopharma 13 Vitaeris Enters into Licensing Agreement with Alder BioPharma for Clazakizumab 14 Alder Biopharma Raises USD100 Million in Private Placement of Preferred Stock 15 Alder BioPharma Raises USD172.5 Million in Public Offering of Shares 16 Alder BioPharma Raises USD143.8 Million in Public Offering of Shares 18 Alder BioPharma Raises USD230 Million in Public Offering of Shares 20 Alder BioPharma Raises USD203.6 Million in Public Offering of Shares 22 Alder Biopharma Raises USD88.8 Million in IPO 24 Alder Biopharma Completes Underwriters Exercise of Over-Allotment Option of Public Offering of 2.5% Notes Due 2025 for USD287.5 Million 26 Alder Biopharmaceuticals Inc, Key Competitors 28 Alder Biopharmaceuticals Inc, Key Employees 29 Alder Biopharmaceuticals Inc, Subsidiaries 30List of Figures Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2 Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2 Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2 Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2 Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6 Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7 Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8 Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9